Halting renal fibrosis: An unexpected role for mTORC2 signaling

Kidney International

Volumn 88, Issue 3, 2015, Pages 437-439

  Grahammer, Florian ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; ALPHA SMOOTH MUSCLE ACTIN; CONNECTIVE TISSUE GROWTH FACTOR; EVEROLIMUS; FIBRONECTIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; RAPAMYCIN; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SCAFFOLD PROTEIN; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA; CARRIER PROTEIN; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TRANSFORMING GROWTH FACTOR BETA1;

ALPHA SMOOTH MUSCLE ACTIN GENE; CELL SURVIVAL; CHRONIC KIDNEY DISEASE; EXTRACELLULAR MATRIX; FIBRONECTIN GENE; FOCAL GLOMERULOSCLEROSIS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; HYDROPHOBICITY; IMMUNOFLUORESCENCE; INHIBITION KINETICS; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM CELL; KIDNEY POLYCYSTIC DISEASE; LONG TERM EXPOSURE; NEPHROTOXICITY; NONHUMAN; NRK 49F CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; UPREGULATION; URETER OBSTRUCTION; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; FIBROBLAST; KIDNEY; KIDNEY DISEASE; MALE; METABOLISM;

ANIMALS; CARRIER PROTEINS; FIBROBLASTS; KIDNEY; KIDNEY DISEASES; MALE; MULTIPROTEIN COMPLEXES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84940770065     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.137     Document Type: Note

References (9)

1. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol. 2010; 21: 1819-1834.
2. Li J, Ren J, Liu X, et al. Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis. Kidney Int. 2015; 88: 515-527.
3. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149: 274-293.
4. Jiang L, Xu L, Mao J, et al. Rheb/mTORC1 signaling promotes kidney fibroblast activation and fibrosis. J Am Soc Nephrol. 2013; 24: 1114-1126.
5. Budde K, Becker T, Arns W, et al. Everolimusbased, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011; 377: 837-847.
6. Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010; 363: 830-840.
7. Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis. 2007; 49: 310-317.
8. Ravichandran K, Zafar I, Ozkok A, et al. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease. Nephrol Dial Transplant. 2015; 30: 45-53.
9. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebocontrolled trial. Lancet. 2013; 381: 817-824.